Related Experiment Video
Updated: Jul 19, 2025
Synergetic Use of Neural Precursor Cells and Self-assembling Peptides in Experimental Cervical Spinal Cord Injury
Published on: February 23, 2015
Rolipram-loaded PgP nanoparticle reduces secondary injury and enhances motor function recovery in a rat moderate
Jun Gao1, Min Kyung Khang1, Zhen Liao1
1Drug Design Delivery and Development (4D) Laboratory, Department of Bioengineering, Clemson University, Clemson, SC, USA.
Abstract:
Spinal cord injury (SCI) results in immediate axonal damage and cell death, as well as a prolonged secondary injury consist of a cascade of pathophysiological processes. One important aspect of secondary injury is activation of phosphodiesterase 4 (PDE4) that leads to reduce cAMP levels in the injured spinal cord. We have developed an amphiphilic copolymer, poly (lactide-co-glycolide)-graft-polyethylenimine (PgP) that can deliver Rolipram, the PDE4 inhibitor. The objective of this work was to investigate the effect of rolipram loaded PgP (Rm-PgP) on secondary injury and motor functional recovery in a rat moderate contusion SCI model. We observed that Rm-PgP can increase cAMP level at the lesion site, and reduce secondary injury such as the inflammatory response by macrophages/microglia, astrogliosis by activated astrocytes and apoptosis as well as improve neuronal survival at 4 weeks post-injury (WPI). We also observed that Rm-PgP can improve motor functional recovery after SCI over 4 WPI.
Insights
This study shows that a novel drug delivery system (Rm-PgP) can reduce secondary injury after spinal cord injury (SCI) by increasing cAMP levels. This leads to improved neuronal survival and motor function recovery in rats.
Area of Science:
- Neuroscience
- Biomaterials Science
- Pharmacology
Background:
- Spinal cord injury (SCI) causes immediate damage and secondary injury, including inflammation and cell death.
- Phosphodiesterase 4 (PDE4) activation in SCI reduces crucial cAMP levels.
- Developing effective treatments for SCI secondary injury and functional recovery remains a significant challenge.
Purpose of the Study:
- To investigate the therapeutic effects of rolipram-loaded poly (lactide-co-glycolide)-graft-polyethylenimine (Rm-PgP) on secondary injury.
- To evaluate the impact of Rm-PgP on motor functional recovery following a rat moderate contusion SCI model.
- To assess the modulation of cAMP levels and secondary injury markers by Rm-PgP at the lesion site.
Main Methods:
- Development of an amphiphilic copolymer (PgP) for delivering the PDE4 inhibitor, rolipram.
- Administration of rolipram-loaded PgP (Rm-PgP) to rats with moderate contusion SCI.
- Assessment of cAMP levels, inflammatory responses (macrophages/microglia), astrogliosis, apoptosis, neuronal survival, and motor function recovery at 4 weeks post-injury.
Main Results:
- Rm-PgP successfully increased cAMP levels at the SCI lesion site.
- Treatment with Rm-PgP significantly reduced secondary injury markers, including inflammation, astrogliosis, and apoptosis.
- Enhanced neuronal survival and improved motor functional recovery were observed in rats treated with Rm-PgP post-SCI.
Conclusions:
- The developed Rm-PgP system effectively delivers rolipram to mitigate SCI secondary injury.
- Rm-PgP demonstrates potential as a therapeutic strategy to promote neuronal survival and functional recovery after spinal cord injury.
- Targeting PDE4 with Rm-PgP offers a promising approach for managing the complex pathophysiology of SCI.
